论文部分内容阅读
肿瘤坏死因子相关凋亡诱导配体(tumor necrosis factor related apoptosis inducing ligand,TRAIL)只有与细胞膜上死亡受体结合才能促使癌细胞凋亡,一旦细胞膜上的死亡受体发生缺失或失去活性,将使癌细胞对TRAIL极为耐受。近年来,对死亡受体的研究发现,死亡受体异常表达可能是死亡受体在细胞膜上发生功能性缺失的最主要原因。该文主要探究肿瘤细胞中死亡受体在转录调控、翻译后修饰、转运和内化过程中的异常情况,期望为今后研发克服TRAIL耐受的联合药物及癌症治疗提供参考。
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) can induce apoptosis of cancer cells only by binding to the death receptor on the cell membrane. Once the death receptor on the cell membrane is deleted or inactivated, Cancer cells are extremely tolerant to TRAIL. In recent years, the study of death receptors found that the abnormal expression of death receptors may be the leading cause of functional loss of death receptors on the cell membrane. This article mainly explores the abnormality of death receptors in tumor cells during transcriptional regulation, posttranslational modification, transport and internalization, and hopes to provide reference for future development of combination therapy and cancer therapy to overcome TRAIL tolerance.